Type II tyrosinemia: Difference between revisions
No edit summary |
mNo edit summary |
||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}}; {{AE}} | |||
{{Infobox_Disease | | {{Infobox_Disease | | ||
Name = {{PAGENAME}} | | Name = {{PAGENAME}} | | ||
Line 11: | Line 15: | ||
OMIM_mult = | | OMIM_mult = | | ||
MedlinePlus = | | MedlinePlus = | | ||
eMedicineSubj = | eMedicineSubj = | ||
eMedicineTopic = | eMedicineTopic = | | ||
MeshID = D020176 | | MeshID = D020176 | | ||
}} | }} | ||
==Overview== | ==Overview== | ||
'''Type II tyrosinemia''' is caused by a deficiency of the enzyme [[tyrosine aminotransferase]] ({{EC number|2.6.1.5}}), encoded by the gene ''TAT''. | '''Type II tyrosinemia''' is caused by a deficiency of the enzyme [[tyrosine aminotransferase]] ({{EC number|2.6.1.5}}), encoded by the gene ''TAT''. | ||
==Historical Perspective== | |||
==Classification== | |||
==Pathophysiology== | ==Pathophysiology== | ||
Tyrosine aminotransferase is the first in a series of five enzymes that converts tyrosine to smaller molecules, which are excreted by the kidneys or used in reactions that produce energy. This form of the disorder can affect the [[eye]]s, [[skin]], and mental development. | Tyrosine aminotransferase is the first in a series of five enzymes that converts tyrosine to smaller molecules, which are excreted by the kidneys or used in reactions that produce energy. This form of the disorder can affect the [[eye]]s, [[skin]], and mental development. | ||
==Causes== | |||
==Differentiating {{PAGENAME}} from Other Diseases== | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Type II tyrosinemia occurs in fewer than 1 in 250,000 individuals. | Type II tyrosinemia occurs in fewer than 1 in 250,000 individuals. | ||
==Risk Factors== | |||
==Screening== | |||
==Natural History, Complications, and Prognosis== | |||
===Natural History=== | |||
===Complications=== | |||
===Prognosis=== | |||
==Diagnosis== | ==Diagnosis== | ||
===Symptoms=== | ===Diagnostic Criteria=== | ||
===History and Symptoms=== | |||
Symptoms often begin in early childhood and include [[excessive tearing]], abnormal sensitivity to light ([[photophobia]]), [[eye pain]] and [[eye redness]], and painful skin lesions on the palms and soles. About half of individuals with type II tyrosinemia are also mentally retarded. | Symptoms often begin in early childhood and include [[excessive tearing]], abnormal sensitivity to light ([[photophobia]]), [[eye pain]] and [[eye redness]], and painful skin lesions on the palms and soles. About half of individuals with type II tyrosinemia are also mentally retarded. | ||
===Physical Examination=== | |||
===Laboratory Findings=== | |||
===Imaging Findings=== | |||
===Other Diagnostic Studies=== | |||
==Treatment== | |||
===Medical Therapy=== | |||
===Surgery=== | |||
===Prevention=== | |||
==References== | |||
{{reflist|2}} | |||
{{Amino acid metabolic pathology}} | {{Amino acid metabolic pathology}} | ||
[[Category: | [[Category:Endocrinology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 20:20, 20 July 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Type II tyrosinemia | |
Tyrosine | |
ICD-10 | E70.2 |
ICD-9 | 270.2 |
OMIM | 276600 |
DiseasesDB | 13486 |
eMedicine | =/topic{{{eMedicineTopic}}}.htm eMedicineTopic =/{{{eMedicineTopic}}} |
MeSH | D020176 |
Overview
Type II tyrosinemia is caused by a deficiency of the enzyme tyrosine aminotransferase (EC 2.6.1.5), encoded by the gene TAT.
Historical Perspective
Classification
Pathophysiology
Tyrosine aminotransferase is the first in a series of five enzymes that converts tyrosine to smaller molecules, which are excreted by the kidneys or used in reactions that produce energy. This form of the disorder can affect the eyes, skin, and mental development.
Causes
Differentiating Type II tyrosinemia from Other Diseases
Epidemiology and Demographics
Type II tyrosinemia occurs in fewer than 1 in 250,000 individuals.
Risk Factors
Screening
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Symptoms often begin in early childhood and include excessive tearing, abnormal sensitivity to light (photophobia), eye pain and eye redness, and painful skin lesions on the palms and soles. About half of individuals with type II tyrosinemia are also mentally retarded.